Worldcare Clinical
Worldcare Clinical is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study enrolled 451 participants at 120 investigative sites in 24 countries from 24 April 2018 to 31 December 2025.
- Because of an unexpected slowing of the EFS rate, the pre-planned second interim IRF-EFS analysis was converted to the final IRF-EFS analysis, with longer follow-up than originally planned.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
Sponsor Oculis Operations S.a.r.l.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
Sponsor Oculis Operations S.a.r.l.
- Start (EU)
- Latest update
- Estimated end
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination with Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and < 70 Years with Severe or Moderate Hemophilia a Without FVIII Inhibitors on Emicizumab Prophylaxis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
C0371002 - Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-R338L) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Single-Arm Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Platinum-Based Concurrent Chemoradiation
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared with Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects with Diabetic Macular Edema (OXEYE).
Sponsor Oxular IE Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreak 201)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial,Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
Sponsor Advenchen Laboratories LLC
- Start (EU)
- Latest update
- Estimated end
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [CERPASS]
Sponsor Replimune Group Inc.
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Patients From Birth to 12 Months of Age with Hemophilia A without Inhibitors
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Worldcare Clinical?
The 2026-10-09 snapshot links Worldcare Clinical to 15 distinct CTIS trials. Recorded services include Imaging, Central Imaging Reader for SM (Specular microscopy), Imaging Vendor, Central Imaging, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Worldcare Clinical?
The most frequently recorded therapeutic areas are Ophthalmology, Solid Tumor Oncology, Blood Disorders, Endocrinology. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Worldcare Clinical conducted?
The linked trials record locations in 15 countries, including Spain, France, Germany, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Worldcare Clinical delivered services.
What can this page tell me about Worldcare Clinical's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Worldcare Clinical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- WORLDCARE CLINICAL
- Worldcare Clinical LLC